Clareo Health | Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
With
Academic GI Cancer Consortium (AGICC)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically diagnosis of metastatic ductal adenocarcinoma of the pancreas.
No prior radiotherapy, surgery chemotherapy or investigational therapy for metastatic disease. Prior adjuvant therapy with 5-FU or gemcitabine (± gemcitabine post radiation) administered as radiosensitizer allowed, provided at least 6 months have elapsed between the last dose and study registration
Tumor tissue available (Archival 6 months old or de novo biopsy)
Measurable disease as per RECIST 1.1
Performance Status (ECOG) 0 or 1
You may not be if
Symptomatic brain metastases requiring steroids
Prior therapy with gamma secretase inhibitors or other Notch pathway inhibitor
Major surgery within 4 weeks of registration in the current study
Known hypersensitivity to gemcitabine or nab-paclitaxel or any of the excipients
Current or anticipated need for food or drugs that are strong/moderate CYP3A4 inhibitors or inducers
Diagnosis of any second malignancy within 3 years prior to registration
